Kiniksa Pharmaceuticals International KNSA
NASDAQ KNSA
$78.95 +1.86 (+2.41%)
As of: Sep 9, 2026 · 3:31 PM EDT

Kiniksa Pharmaceuticals International (KNSA) Prepaid Assets (2017 - 2026)

Kiniksa Pharmaceuticals International's (KNSA) quarterly Prepaid Assets came in at $48.3 million in Q2 2026, up 48.85% on a YoY basis from $32.4 million in Q2 2025, and up 62.5% quarter-over-quarter from $29.7 million in Q1 2026.

Analysis

Kiniksa Pharmaceuticals International (KNSA) Prepaid Assets (2017 - 2026) Analysis & Trends

Kiniksa Pharmaceuticals International (KNSA) has reported Prepaid Assets for 10 consecutive years, with $48.3 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Prepaid Assets rose 48.85% year-over-year to $48.3 million; the trailing twelve-month figure through Jun 2026 stood at $48.3 million (up 48.85% YoY), and the FY2025 full-year result was $42.6 million, up 112.18% from the prior year.
  • Prepaid Assets improved to $48.3 million in Q2 2026 per KNSA's latest filing, from $29.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $48.3 million in Q2 2026 and bottomed at $10.5 million in Q1 2022.
  • Historically, Prepaid Assets has averaged $23.5 million across 5 years, with a median of $22.8 million in 2024.
  • The sharpest annual moves came in 2023 and 2024: Prepaid Assets dropped 11.18% in 2023, then jumped 116.67% in 2024.
  • Over 5 years, Prepaid Assets stood at $10.5 million in 2022, then jumped by 66.44% to $17.5 million in 2023, then increased by 14.52% to $20.1 million in 2024, then soared by 112.18% to $42.6 million in 2025, then climbed by 13.31% to $48.3 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods registered $48.3 million, $29.7 million, and $42.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 212.04 Bn 198.05 Bn 7.24 Bn
2 Gilead Sciences 181.35 Bn 178.17 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.22 Bn 124.37 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.94 Bn 74.94 Bn 3.93 Bn
5 Argenx Se 61.53 Bn 56.34 Bn 1.37 Bn
6 Moderna 54.25 Bn 49.11 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.41 Bn 31.10 Bn 992.69 Mn
8 Biogen 31.19 Bn 29.91 Bn 1.96 Bn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn
10 Kiniksa Pharmaceuticals International 6.12 Bn 5.60 Bn 220.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 48.29 Mn
Mar 31, 2026 29.71 Mn
Dec 31, 2025 42.61 Mn
Sep 30, 2025 30.29 Mn
Jun 30, 2025 32.44 Mn
Mar 31, 2025 25.43 Mn
Dec 31, 2024 20.08 Mn
Sep 30, 2024 33.95 Mn
Jun 30, 2024 26.95 Mn
Mar 31, 2024 13.77 Mn
Dec 31, 2023 17.54 Mn
Sep 30, 2023 26.40 Mn
Jun 30, 2023 12.44 Mn
Mar 31, 2023 13.16 Mn
Dec 31, 2022 10.54 Mn
Sep 30, 2022 15.31 Mn
Jun 30, 2022 14.01 Mn
Mar 31, 2022 10.52 Mn
Dec 31, 2021 6.59 Mn
Sep 30, 2021 8.50 Mn